Company Analysis
Sign in

NovaBridge Biosciences (NBP)

Nasdaq: NBP · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.6
◀ Past 5.1● Present 2.7▶ Future 5.9
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2023, as filed
RevenueCN¥27.6M+112.5%
Net income-CN¥1.47B+41.5%
Earnings per shareCN¥-7.66+42.0%
Operating cash flown/a
CashCN¥2.20B-33.5%
Debtn/a
Shareholders’ equityCN¥1.72B-41.0%
Shares, diluted191.4M+0.9%
Return on equity-85.3%
The recordfrom its filings
Filings in 202675
Newest filingNov 5 · SCHEDULE 13D/A
Annual reportApr 7, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$200,000
Insider buys, 12 months$600,000
Patents granted17
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
17181920212223
As filed, in CNY. Nothing here is a forecast.

News

Oct 19, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 11, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton NBP · research, not advice